Source:http://linkedlifedata.com/resource/pubmed/id/10409505
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
1999-10-8
|
pubmed:abstractText |
Erythropoietin is an essential growth factor that promotes survival, proliferation, and differentiation of mammalian erythroid progenitor cells. Erythropoietin(-/-) and erythropoietin receptor(-/-) mouse embryos die around embryonic day 13.5 due, in part, to failure of erythropoiesis in the fetal liver. In this study, we demonstrated a novel role of erythropoietin and erythropoietin receptor in cardiac development in vivo. We found that erythropoietin receptor is expressed in the developing murine heart in a temporal and cell type-specific manner: it is initially detected by embryonic day 10.5 and persists until day 14.5. Both erythropoietin(-/-) and erythropoietin receptor(-/-) embryos suffered from ventricular hypoplasia at day 12-13 of gestation. This defect appears to be independent from the general state of hypoxia and is likely due to a reduction in the number of proliferating cardiac myocytes in the ventricular myocardium. Cell proliferation assays revealed that erythropoietin acts as a mitogen in cells isolated from erythropoietin(-/-) mice, while it has no effect in hearts from erythropoietin receptor(-/-) animals. Erythropoietin(-/-) and erythropoietin receptor(-/-) embryos also suffered from epicardium detachment and abnormalities in the vascular network. Finally, through a series of chimeric analysis, we provided evidence that erythropoietin acts in a manner which is non-cell-autonomous. Our results elucidate a novel role of erythropoietin in cardiac morphogenesis and suggest a combination of anemia and cardiac failure as the cause of embryonic lethality in the erythropoietin(-/-) and erythropoietin receptor(-/-) animals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0950-1991
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
126
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3597-605
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10409505-Animals,
pubmed-meshheading:10409505-Cell Differentiation,
pubmed-meshheading:10409505-Cell Division,
pubmed-meshheading:10409505-Cells, Cultured,
pubmed-meshheading:10409505-Chimera,
pubmed-meshheading:10409505-Erythropoietin,
pubmed-meshheading:10409505-Gene Expression Regulation, Developmental,
pubmed-meshheading:10409505-Heart,
pubmed-meshheading:10409505-Heart Defects, Congenital,
pubmed-meshheading:10409505-Mice,
pubmed-meshheading:10409505-Mice, Knockout,
pubmed-meshheading:10409505-Morphogenesis,
pubmed-meshheading:10409505-Myocardium,
pubmed-meshheading:10409505-Receptors, Erythropoietin,
pubmed-meshheading:10409505-Stem Cells
|
pubmed:year |
1999
|
pubmed:articleTitle |
Inactivation of erythropoietin leads to defects in cardiac morphogenesis.
|
pubmed:affiliation |
Howard Hughes Medical Institute and Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, CA 90095-1735, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|